Abstract

INSOMNIA

Sejal Waghmare*

.

Abstract

The last ten year have seen development and publication of numerous national and international guidelines devoted to the diagnosis and treatment of insomnia. These include guidelines by the American college of physician (ACP), the American Academy of sleep medicine (AASM), the British Sleep Society (BSS), the German sleep society (GSS), and the European sleep Research society (ESRS). Though coming from very diverse authors and backgrounds, these guidelines by and large agree concerning the therapeutics recommendations: cognitive behavioral treatments of insomnia (CBT-I), a multicomponent psychotherapeutics intervention, is unequivocally recommended as a first-line treatment. In this report, we will focus on the most recent guideline update from the ESRS, which was published in November 2023. After suggesting a careful diagnostic procedure, CBT-I, both applied face to face (F2F) or digitally (dCBT-I), is again recommended as a first-line treatment based on the available evidence. Hypnotic medications like benzodiazepines (BZ), benzodiazepines receptor agonists (BZRA), sedating antidepressants, and other are approved for short-term-treatment of up to four weeks. Orexin receptor antagonists (i.e., daridorexant) and prolonged release melatonin are considered as option for longer-term.

Keywords: The last ten year have seen development and publication of numerous national and international guidelines devoted to the diagnosis and treatment of insomnia.